A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Latest Information Update: 03 May 2024
At a glance
- Drugs Brentuximab vedotin (Primary) ; Crizotinib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Ifosfamide; Methotrexate
- Indications Anaplastic large cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 26 Sep 2023 Planned End Date changed from 2 Aug 2022 to 22 Sep 2024.
- 22 Dec 2022 Status changed from active, no longer recruiting to completed. according to the results published in the Journal of Clinical Oncology.
- 19 Dec 2022 Results of the Crizotinib arm (n=66) published in the Journal of Clinical Oncology